Abstract
THE JOURNAL OF CLINICAL HYPERTENSION 413 Chronic kidney disease is the most common medically treatable cause of secondary hypertension. It most often results from poorly controlled diabetes and/or elevated blood pressure (BP).1 Kidney disease has various stages and may present with albuminuria (>200 mg/d) or proteinuria (>300 mg/d) as a laboratory marker. Some of the most common antihypertensive therapies used in the treatment of hypertension in people with kidney disease involve agents that inhibit the renin-angiotensin system (RAS). The compelling indications for use of these medications in kidney disease derives from data from a variety of studies in advanced (stage 3 or 4) nephropathy (ie, glomerular filtration rate [GFR] >15 but 1.4 mg/dL and >300 mg/d of proteinuria), the use of ACE inhibitors and ARBs resulted in similar outcomes on nephropathy progression when compared with other classes of antihypertensive drugs. This was true for cardiovascular outcomes including stroke.6 In a more recent analysis by Casas and colleagues,7 databases were searched up until January 2005 for randomized trials reviewing the use of antihypertensive drugs and progression of kidney disease. Primary end points in 127 trials were evaluated (ie, doubling of serum creatinine and/or development of end-stage renal disease, as well as secondary continuous markers of renal outcomes www.lejacq.com ID: 7234 E d i t o r i a l
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call